Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q4 2021 Earnings Presentation
30 slides from Bactiguard Holding Ab's earnings presentation, Feb 9, 2022
Slide 1: Investor presentation Q4 2021
Investor presentation Q4 2021 9 February, 2022 Anders Göransson, CEO Gabriella Björknert Caracciolo, CFO
Slide 2: Agenda
AGENDA New focused growth Expanded partnership with Q4 2021 Review and strategy and long-term Zimmer Biomet results financial targets 2
Slide 3: Expanded global partnership with Zimmer Biomet
Expanded global partnership with Zimmer Biomet Covering multiple product segments • License and development fees of USD 1.5 million, payable in 2022 • USD 7.5 million in milestone payments, contingent on U.S. regulatory clearance for different product categories • Royalties on net sales following co
Slide 4: Developing new standards of care in orthopedics
Developing new standards of care in orthopedics 2022 Feb Global partnership 2021 June extended to include EMEA launch of hips, knees and other ZNN Bactiguard extremities 2021 Jan ZNN Bactiguard CE mark 2019 Sept Zimmer Biomet License Agreement for trauma applications 2018 Dec First Bactiguard coated
Slide 5: Orthopedic product range
Orthopedic product range Orthopedic market segments and share of global market Other Arthroscopy Cranio maxillofacial 9% 10% Cranio Maxillofacial Trauma 3% 13% Shoulders Hip 15% Thoracic Hips 21% Spine Sports medicine 17% Knee 13% Knees Trauma Orthobiologics Total market 49 US Billion 1. Source: Glo
Slide 6: Zimmer Biomet a major global players in orthopedics
Zimmer Biomet a major global players in orthopedics Revenues and market shares DePuy Synthes Inc 18% Other 33% 15% Stryker Corp 4% Arthrex 14% 7% 9% Zimmer Biomet Smith & Nephew Medtronic 1. Source: ZB AR, GlobalData, 2020 data 6
Slide 7: Agenda
AGENDA New focused growth Expanded partnership with Q4 2021 Review and strategy and long-term Zimmer Biomet results financial targets 7
Slide 8: Bactiguard – fourth quarter 2021
Bactiguard – fourth quarter 2021 Key Financials, Q4 2021 (Q4 2020) Sales EBITDA Net Profit Operating cash flow MSEK 46.1 (55.6) • License 24.7 (33.4) MSEK -12.1 (4.9) MSEK -25.4 (-10.8) MSEK -16.8 (3.9) • BIP sales 17.3 (16.9) Q3 2021: Directed new share issue to AMF, of SEK 228 million 1,500,000 B
Slide 9: Business Highlights – License
Business Highlights – License BD business recovering and ZNN Bactiguard EMEA launch continues LICENSE BUSINESS • BD business recovered to pre-covid levels on a yearly basis • Zimmer Biomet partnership further deepened and expanded • Zimmer® Natural Nail® (ZNN) Bactiguard-implants launched across Eur
Slide 10: Business Highlights – Bactiguard portfolio
Business Highlights – Bactiguard portfolio Strong growth in focus areas: BIP Catheters and Wound management portfolio BACTIGUARD PORTFOLIO Customer / Patient • Strong growth in BIP Cathethers especially in markets with investment in salesforce Own sales force Distributor Bactiguard / Distributor Ser
Slide 11: Building patient centric commercial capabilities
Building patient centric commercial capabilities Expansion of commercial resources and capabilities to support our growth strategy initiated Medical Affairs & Product / Thought leadership Market Access License development Digitalization Strategic partnership Communication Sales and Distributor Excel
Slide 12: Global outlook
Global outlook Covid-19 situation by WHO • Over 394 million cases • App. 5.7 million deaths • Rapid increase of number of infected in Dec/Jan due to Omicron variant… • …which is milder and combined with the increase in vaccination rates has reduced the number of severe Covid- 19 cases and the impact
Slide 13: Financial update
Financial update 13
Slide 14: Stable rolling 12-month revenue
Stable rolling 12-month revenue • BD license revenue was lower in Q4 compared to Q3 but stabile on a yearly basis • BIP revenues growth mainly driven by Wound Care and BIP catheters. • Still Uncertainly regarding the Covid development in certain markets • New license revenue related to product devel
Slide 15: Financial overview
Financial overview Q4 2021 vs Q4 2020 • Revenue decline of -17%, currency adjusted -22%, resulting in total MSEK 46.1 (55.6) . - Q4 2020 large order from Wellead • EBITDA of MSEK -12.1 (4.9) with an EBITDA-margin of -26% (9%) mainly due to revenue mix and investments in growth strategy FY 2021 vs FY
Slide 16: Cash flow and liquidity
Cash flow and liquidity Cash and cash equivalent Cash flow and liquidity, MSEK • Credit facility with SEB renegotiate in Dec 2021 300 3 904 733 16 626 308 25 178 443 8 800 163 0 0 40 due to directed new shares issue*: 21 199 837 - Extended two years to December 2024 250 30 - covenants to mirror the
Slide 17: Agenda
AGENDA New focused growth Expanded partnership with Q4 2021 Review and strategy and long term Zimmer Biomet results financial targets 17
Slide 18: The threat of Anti Microbial Resistance (AMR)
The threat of Anti Microbial Resistance (AMR) Not only a future nightmare…It is a problem we need to address right now 1.3 million annual deaths in 2019 >10 million annual deaths by 2050 • 4.95 million deaths associated with and 1.3 million deaths directly caused by AMR (2019) • AMR is a major globa
Slide 19: Our Expanding opportunities
Our Expanding opportunities More than preventing hospital acquired infection Surgical Wound infections infections Hospital Acquired Infections Hospital Acquired Infections Dental Animal infections infections Secondary infections Our growing product portfolio has opened up for several new opportuniti
Slide 20: Vision
VISION Keeping people safe from infections 20
Slide 21: Patient focused strategy to leverage scalable business model
Patient focused strategy to leverage scalable business model Licensing 1 Orthopedics 2 Nephrology 3 Urology 4 Critical care / CVC 5 Dental 6 Wound management BIP Sales 21
Slide 22: Major potential for growth in focus Therapeutic areas
Major potential for growth in focus Therapeutic areas Therapeutic area Market size BnUSD Orthopedics 40 Nephrology 7 Urology 3 Dental 9 Critical care / CVC 11 Wound management 10 Please note, numbers 22 being further assessed Source: GlobalData 2020, Own analysis,
Slide 23: Existing business strong foundation for expansion
Existing business strong foundation for expansion Therapeutic area Market size BnUSD Own products License partners Orthopedic Orthopedics 40 implants Nephrology 7 Urinary Urology 3 catheters Dental 9 Critical care / ETT1 CVC 11 CVC2 Wound Wound care management 10 Surgical sutures 1 Entotracheal tube
Slide 24: Focus on high potential geographies
Focus on high potential geographies Global MedTech market United States 41% Europe 27% Rest of world 32% Source: GlobalData 24
Slide 25: Right timing to fuel growth
Right timing to fuel growth 1 2 3 Strong clinical evidence Capital for growth Commercial capabilities • >200 million catheters used with no • > 220 mSEK raised during the fall of • Strengthened commercial capabilities reported adverse event 2021 to fund a fact based, focused growth for continued exp
Slide 26: Updated long term financial targets
Updated long term financial targets Revenue 2026 ”The transformation of the Bactiguard • Annual revenue of at least 1 billion SEK (new) organisation will impact the coming one to two year period, while we expect rapidly accelerating profitability in the Profit 2026 years 2024 through 2026.” • Annua
Slide 27: Agenda
AGENDA New focused growth Expanded partnership with Q4 2021 Review and strategy and long term Zimmer Biomet results financial targets 27
Slide 28: Questions & Answers
Questions & Answers Anders Göransson Gabriella Björknert Caracciolo CEO CFO +46 8 440 58 80 +46 8 440 58 80 anders.goransson@bactiguard.com gabriella.caracciolo@bactiguard.com 28
Slide 29: Bactiguard on the outside – safe on the inside
Bactiguard on the outside – safe on the inside 29 29
Slide 30: Upcoming events and financial reports
Upcoming events and financial reports 30